Intersect ENT

Intersect ENT to Report Second Quarter 2019 Financial Results

Retrieved on:

Monday, July 15, 2019

Medical devices, Health, Hospitals, Pharmaceutical, Intersect ENT, ENT, Otorhinolaryngology

Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release second quarter financial results on August 1, 2019.

Key Points:

Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release second quarter financial results on August 1, 2019.
To access the conference call via the internet, go to the "Investor Relations" page of the company's website at www.intersectENT.com .
To access the live conference call via phone, dial (844) 850-0548 and ask to join the Intersect ENT call.
Intersect ENT is dedicated to transforming ear, nose and throat care by providing innovative, clinically meaningful therapies to physicians and patients.

Intersect ENT Announces Appointment of Thomas A. West as CEO

Retrieved on:

Thursday, June 27, 2019

Medical devices, Health, Hospitals, Pharmaceutical, Intersect ENT, ENT

Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the appointment of Thomas (Tom) A.

Key Points:

Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the appointment of Thomas (Tom) A.
Mr. West also oversaw a steady cadence of innovation, yielding multiple FDA approvals across 11 consecutive quarters since 2016.
Tom is a proven healthcare leader bringing more than two decades of medical technology experience to Intersect ENT.
Intersect ENT is a registered trademark of Intersect ENT, Inc.

Robbins Arroyo LLP: Intersect ENT, Inc. (XENT) Misled Shareholders According to a Recently Filed Lawsuit

Retrieved on:

Friday, May 24, 2019

Professional services, Legal, Intersect ENT, ENT, Otorhinolaryngology

Intersect ENT is a commercial drug delivery company that purports to develop products for patients with ear, nose, and throat conditions.

Key Points:

Intersect ENT is a commercial drug delivery company that purports to develop products for patients with ear, nose, and throat conditions.
However, Intersect failed to disclose to investors that it lacked adequate reimbursement representatives to ensure physicians had access to SINUVA.
In May 2019, Intersect ENT disclosed a first quarter 2019 loss of $10.8 million and lowered guidance for the remainder of 2019.
On this news, Intersect ENT's share price fell more than 25% to close at $25.10 per share on May 7, 2019.

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Intersect ENT, Inc.

Retrieved on:

Wednesday, May 22, 2019

Professional services, Legal, Intersect ENT, Class action, XHNT-FM, ENT

Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingJuly 15, 2019deadline to file a lead plaintiff motion in the class action filed on behalf of Intersect ENT, Inc. (Intersect ENT or the Company) (NASDAQ: XENT ) investors who purchased securities betweenAugust 1, 2018 and May 6, 2019, inclusive (the Class Period).

Key Points:

Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingJuly 15, 2019deadline to file a lead plaintiff motion in the class action filed on behalf of Intersect ENT, Inc. (Intersect ENT or the Company) (NASDAQ: XENT ) investors who purchased securities betweenAugust 1, 2018 and May 6, 2019, inclusive (the Class Period).
Then, on May 6, 2019, the Company disclosed a first quarter 2019 loss of $10.8 million and lowered guidance for the remainder of 2019.
If you purchased or otherwise acquired Intersect ENT securities during the Class Period you may move the Court no later thanJuly 15, 2019 to request appointment as lead plaintiff in this putative class action lawsuit.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Scott+Scott Attorneys at Law LLP Announces the Filing of a Securities Class Action Against Intersect ENT, Inc. (XENT)

Retrieved on:

Tuesday, May 21, 2019

Professional services, Legal, Intersect ENT, Securities Class Action, Class action

Scott+Scott Attorneys at Law LLP (Scott+Scott), an international shareholder and consumer rights litigation firm, is notifying investors that a securities class action lawsuit has been filed against Intersect ENT, Inc. (Intersect or the Company) (NASDAQ: XENT) and other defendants, related to alleged violations of federal securities laws.

Key Points:

Scott+Scott Attorneys at Law LLP (Scott+Scott), an international shareholder and consumer rights litigation firm, is notifying investors that a securities class action lawsuit has been filed against Intersect ENT, Inc. (Intersect or the Company) (NASDAQ: XENT) and other defendants, related to alleged violations of federal securities laws.
If you purchased Intersect stock between August 1, 2018 and May 6, 2019, you are encouraged to contact Jonathan Zimmerman at (888) 398-9312 for more information.
Intersect is a commercial drug delivery company that purports to develop products for patients with ear, nose and throat conditions.
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Intersect ENT, Inc. Investors (XENT)

Retrieved on:

Thursday, May 16, 2019

Professional services, Legal, Economy, Finance, Money, Intersect ENT, XHNT-FM, Investor

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Intersect ENT, Inc.(Intersect ENT or the Company) (NASDAQ: XENT ) securities between August 1, 2018 and May 6, 2019, inclusive (the Class Period).

Key Points:

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Intersect ENT, Inc.(Intersect ENT or the Company) (NASDAQ: XENT ) securities between August 1, 2018 and May 6, 2019, inclusive (the Class Period).
Intersect ENT investors have until July 15, 2019 to file a lead plaintiff motion.
Investors suffering losses on their Intersect ENT investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Intersect ENT, Inc. Investors (XENT)

Retrieved on:

Thursday, May 16, 2019

Professional services, Legal, Intersect ENT, Securities Exchange Act

Glancy Prongay & Murray LLP (GPM)announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Yaron v. Intersect ENT, Inc. et al., (Case No.

Key Points:

Glancy Prongay & Murray LLP (GPM)announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Yaron v. Intersect ENT, Inc. et al., (Case No.
3:19-cv-02647), on behalf of persons and entities that purchased or otherwise acquired Intersect ENT, Inc. (NASDAQ: XENT ) (Intersect ENT or the Company) securities between August 1, 2018 and May 6, 2019, inclusive (the Class Period).
Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act).
Investors are hereby notified that they have60 days from the date of this notice to move the Court to serve as lead plaintiff in this action.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Intersect ENT, Inc. Investors (XENT)

Retrieved on:

Thursday, May 9, 2019

Professional services, Legal, Intersect ENT, NASDAQ, Finance, Economy of the United States, Financial markets

Law Offices of Howard G. Smithannounces an investigation on behalf of Intersect ENT, Inc.(Intersect ENT or the Company) (NASDAQ: XENT ) investors concerning the Company and its officers possible violations of federal securities laws.

Key Points:

Law Offices of Howard G. Smithannounces an investigation on behalf of Intersect ENT, Inc.(Intersect ENT or the Company) (NASDAQ: XENT ) investors concerning the Company and its officers possible violations of federal securities laws.
On May 6, 2019, the Company disclosed a first quarter loss of $10.8 million, as well as a lowered guidance for the remainder of 2019.
In addition to this news, the Company also reported that its CEO of 11 years will be stepping down on June 5th.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Intersect ENT, Inc. Investors

Retrieved on:

Wednesday, May 8, 2019

Professional services, Legal, Intersect ENT, NASDAQ, XHNT-FM, Economy of the United States, Finance, Financial markets

Glancy Prongay & Murray LLP (GPM) announces an investigation on behalf of Intersect ENT, Inc. (Intersect ENT or the Company) (NASDAQ: XENT ) investors concerning the Company and its officers possible violations of federal securities laws.

Key Points:

Glancy Prongay & Murray LLP (GPM) announces an investigation on behalf of Intersect ENT, Inc. (Intersect ENT or the Company) (NASDAQ: XENT ) investors concerning the Company and its officers possible violations of federal securities laws.
On May 6, 2019, the Company disclosed a first quarter loss of $10.8 million, as well as a lowered guidance for the remainder of 2019.
In addition to this news, the Company also reported that its CEO of 11 years will be stepping down on June 5th.
On this news, the Companys share price fell sharply during intraday trading, thereby injuring investors.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Intersect ENT, Inc. Investors (XENT)

Retrieved on:

Tuesday, May 7, 2019

Professional services, Legal, Intersect ENT, NASDAQ, Finance, Economy of the United States, Financial markets

Law Offices of Howard G. Smithannounces an investigation on behalf of Intersect ENT, Inc.(Intersect ENT or the Company) (NASDAQ: XENT ) investors concerning the Company and its officers possible violations of federal securities laws.

Key Points:

Law Offices of Howard G. Smithannounces an investigation on behalf of Intersect ENT, Inc.(Intersect ENT or the Company) (NASDAQ: XENT ) investors concerning the Company and its officers possible violations of federal securities laws.
On May 6, 2019, the Company disclosed a first quarter loss of $10.8 million, as well as a lowered guidance for the remainder of 2019.
In addition to this news, the Company also reported that its CEO of 11 years will be stepping down on June 5th.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.